mRNA Cap analog
Desire for Better
As the mRNA market shifts toward cost efficiency beyond the COVID‑19 era, demand for optimized COGS has become essential.
HanmiCap® is a next‑generation 5′ capping material delivering high performance and cost efficiency through process optimization and IP‑safe structural design.
The development of HanmiCap® is informed by peer‑reviewed research on trinucleotide 5′‑cap analogs. The research provides insights into how structural
modification may influence capping efficiency, mRNA stability, and translation. These findings help guide HanmiCap® as a proprietary 5′‑capping material for
mRNA applications.
HanmiCap® is a next‑generation 5′ capping material delivering high performance and cost efficiency through process optimization and IP‑safe structural design.
The development of HanmiCap® is informed by peer‑reviewed research on trinucleotide 5′‑cap analogs. The research provides insights into how structural
modification may influence capping efficiency, mRNA stability, and translation. These findings help guide HanmiCap® as a proprietary 5′‑capping material for
mRNA applications.
HanmiCap® - Proprietary 5' Cap analogs for in vitro transcription
We have developed proprietary 5' capping materials (HanmiCap®) demonstrating cost-competitiveness and high performances in mRNA R&D.
The reduced cost of HanmiCap® has been achieved through the process optimization in the phosphorylation and purification steps.
The reduced cost of HanmiCap® has been achieved through the process optimization in the phosphorylation and purification steps.
- 01In cap dependent translation manner, specific non-polarity caused by R1 or R2 groups could affect translation level of the capped mRNA. R groups stand for modified moieties.
- 02Due to the introduction of R1 or R2 group, phosphorylation and purification steps are reduced.
- 03To reduce innate immunity for exogenous mRNA.
- 04Complementary binding to TC DNA template.
Product Overview
Cap Analogs
HanmiCap® AG: AG Cap analogs for mRNA-IVT
· HanmiCap® 07
· HanmiCap® 13
Figure 1
HEK-293s Luciferase Readings
HEK-293s Luciferase Readings
Figure 1. HanmiCap® 13 showed 2.87-fold higher in vitro Luciferase
expression against the Commercial Cap AG (3'OMe) after HEK-293s
cell transfection (wildtype UTP)
expression against the Commercial Cap AG (3'OMe) after HEK-293s
cell transfection (wildtype UTP)
Figure 2
HEK-293s Luciferase Readings
HEK-293s Luciferase Readings
Figure 2. HanmiCap® 13 showed 1.86-fold higher in vitro Luciferase
expression against the Commercial Cap AG (3'OMe) after HEK-293s
cell transfection (N1-methylpseudo UTP)
expression against the Commercial Cap AG (3'OMe) after HEK-293s
cell transfection (N1-methylpseudo UTP)
Modified NTPs
PUL( Pseudouridine-5'-Triphosphate )
MUL( N1-Methylpseudouridine-5'-Triphosphate )
Hanmi’s mRNA materials are optimized for high performance with cost‑efficient manufacturing. Based on our GMP manufacturing standards, we are able to support scalable mRNA production from early research to GMP manufacturing.